Ascendis Pharma A/S

About Ascendis Pharma A/S

Ascendis Pharma is a global biopharmaceutical company dedicated to making a meaningful difference in patients' lives. Guided by their core values of Patients, Science, and Passion, they utilize their innovative TransCon technology platform to develop therapies with best-in-class potential for improved safety, efficacy, tolerability, and convenience. Headquartered in Denmark, with research facilities in Germany and offices across Europe and the United States, they focus on Endocrinology Rare Disease and Oncology.

Products & Services

TransCon hGH:A product candidate in the Endocrinology Rare Disease area, aimed at addressing specific hormonal deficiencies.

TransCon PTH:A therapy under development for endocrinology-related conditions.

TransCon IL-2 β/γ:A product candidate in the Oncology area, targeting cancer-related treatments.

SKYTROFA:A trademarked product by Ascendis Pharma, specifics not detailed in content.

Specialties

Endocrinology Rare Disease Oncology TransCon Technology Platform

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 281300000 MR: - FA: approximately $281.3 million FAN: 281300000	D: 2024-09-20 FD: 2024-09-20	8 investors
2	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300,000,000 FAN: 300000000	D: 2024-09-18 FD: 2024-09-18	4 investors
3	RT: Royalty Funding T: - FT: Royalty Funding	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2024-09-03 FD: 2024-09-03	1 investors
4	RT: Royalty Financing T: - FT: Royalty Financing	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2024-09-03 FD: 2024-09-03	1 investors

Public Offering Latest

2024-09-20

$281.3M

8 investors (Pro only)

Public Offering 2024-09-18

$300.0M

Royalty Funding 2024-09-03

$150.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jan Møller Mikkelsen

President and Chief Executive Officer

J

Jethro Ekuta

Chief Regulatory & Safety Officer

S

Sherrie Glass

Chief Business Officer

F

Flemming Steen Jensen

Executive Vice President, Product Supply and Quality

M

Michael Wolff Jensen

Executive Vice President, Chief Legal Officer

S

Stina Singel

Executive Vice President, Head of Clinical Development, Oncology

View 13 more team members with Pro

Unlock Full Team Directory

Recent News